On September 17, 2026 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces a licensing, development, manufacturing and commercialisation agreement with mAbxience, marking another significant step to broaden patient access to high-quality biosimilar medicines worldwide.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement paves the way for the two companies to collaborate on a proposed emicizumab biosimilar, currently in early-stage development. The reference medicine, Hemlibra* (emicizumab), is used to treat patients with haemophilia A1,2, making emicizumab the first haemophilia medicine in the Sandoz biosimilar pipeline. The reference medicine market is worth an estimated USD 5.7 billion in global sales.3
Richard Saynor, Chief Executive Officer, Sandoz, says: "This agreement with mAbxience reflects our continued commitment to our Purpose of pioneering access for patients. The addition of emicizumab strengthens our pipeline and expands our presence in rare diseases, an area where we believe biosimilars can play an important role in addressing unmet patient needs while supporting the long-term sustainability of healthcare systems in the face of rising treatment costs."
Haemophilia A is a rare genetic disorder caused by inadequate or defective factor VIII (FVIII), a blood-clotting protein, which causes prolonged bleeding in patients4. It is the most common form of haemophilia, accounting for approximately 80% of all cases5, with more than half of patients having a severe form of the disease6.
Under the terms of the agreement, Sandoz will have exclusive global commercialisation rights for the proposed emicizumab biosimilar, excluding Argentina, Uruguay and Paraguay, while mAbxience will be responsible for development and manufacturing. Both parties have agreed to keep the financial terms of the agreement confidential. The agreement also provides a basis for the two companies to evaluate potential future collaboration opportunities based on their shared commitment to expanding patient access to biosimilar medicines around the world.
Overall, the collaboration expands the industry-leading Sandoz biosimilar pipeline to 40 assets and builds on the earlier agreements with Henlius for up to 10 assets and Samsung Bioepis for up to five assets. It also represents another milestone in the Company’s strategy to capture a significant share of the unprecedented upcoming biosimilar loss-of-exclusivity market. Sandoz continues to build on its experience as the pioneer and global leader with a portfolio of 13 molecules available in nearly 100 countries.
*Hemlibra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha.
(Press release, Sandoz, SEP 17, 2026, View Source [SID1234670928])